News

Genomic testing can help physicians in the treatment decision process for women with ovarian cancer. As more of these platforms become commercially available, however, physicians must also learn the similarities and differences between each of these tests.

Frontline treatment with ibrutinib plus nab-paclitaxel/gemcitabine did not have a statistically significant benefit in progression-free survival or overall survival compared to placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer.

FDA approval is being sought for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant. Genmab, which co-develops daratumumab with Janssen Biotech, announced that a supplemental Biologics License Application has been initiated with the FDA.

Umbralisib was granted a breakthrough therapy designation by the FDA for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Debra Richardson, MD, discussed the role of PARP inhibitor combinations for frontline maintenance of women with ovarian cancer at the 2019 SGO Winter Meeting.

In an interview with <em>Targeted Oncology</em>, Robert M. Rifkin, MD, highlighted the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.

Anas Younes, MD,&nbsp;discusses findings from a subset analysis from the PHOENIX trial in patients with DLBCL. He also highlights another trial investigating R-CHOP plus a PD-L1 inhibitor in this patient population.

Brian T. Hill, MD, PhD,&nbsp;discusses real-world findings with axi-cel in patients with DLBCL and how these findings can be used to inform practice.

Treatment with&nbsp;durvalumab demonstrated&nbsp;objective responses in approximately one-fourth of patients with&nbsp;microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.

Advances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br /> &nbsp;

SB3, a trastuzumab biosimilar, has been granted FDA approval&nbsp;for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

The dose-adjusted EPOCH-R chemotherapy regimen induced either a complete or partial response in 87% of patients with aggressive B-cell lymphomas with an <em>MYC</em> rearrangement, a population that has had historically poor prognoses with rituximab plus R-CHOP.

In response to a&nbsp;biologics license application submitted for&nbsp;sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies, the FDA has issued a complete response letter to&nbsp;Immunomedics, citing&nbsp;chemistry, manufacturing, and control matters.

At practices with their own pharmacies, many patients are now given the option of picking up prescriptions directly from the clinic, known as medically integrated dispensing. Proponents of this method believe that it provides for better patient outcomes, allows for better tracking of patient adherence, and is substantially more cost effective.&nbsp;

Gabriela S. Hobbs, MD,&nbsp;discusses recent advances in the treatment of myelofibrosis and other MPNs, as well as clinical trials she is currently working on in this space.

Srdan Verstovsek, MD, PhD,&nbsp;discusses the current treatment landscape for patients with essential thrombocytopenia and polycythemia vera and shared details of ongoing clinical trials in the field.

A supplemental biologics license application submitted to the FDA for&nbsp;atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the&nbsp;phase III IMpower130 trial, is seeking the agent&#39;s approval for&nbsp;patients with metastatic nonsquamous non&ndash;small cell lung cancer.

John O. Mascarenhas, MD, discusses with&nbsp;<em>Targeted Oncology&nbsp;</em>the&nbsp;recent advancements being made in the treatment of patients with advanced myelofibrosis and highlights some of the unmet needs that still exist within this space.

Eribulin mesylate (Halaven) demonstrated efficacy in the first-line for patients with aggressive HER2-negative metastatic breast cancer that have received prior treatment with a taxane in the (neo)adjuvant setting, according to results from the phase II MERIBEL trial.

The&nbsp;investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA&nbsp;for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy,&nbsp;BeiGene, the company manufacturing the agent, has announced.

A randomized phase II trial found that nab-paclitaxel showed equivalent efficacy and was well tolerated compared with docetaxel as neoadjuvant therapy in early-stage breast cancer.

ASLAN Pharmaceuticals, the company developing varlitinib (ASLAN001), has announced that a phase II frontline trial investigating the&nbsp;pan-HER inhibitor added to mFOLFOX6 in patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer has missed its primary endpoint.

Cabozantinib has been approved by the FDA for the treatment of&nbsp;patients with hepatocellular carcinoma who previously received sorafenib, Exelixis, the company developing the agent, announced today.

Krish Patel, MD,&nbsp;discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Autologous hematopoietic cell transplantation consolidation after induction therapy may improve progression-free survival in younger, fit patients with mantle cell lymphoma, according to the results of a retrospective analysis recently published in the <em>Journal of Clinical Oncology. </em>

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;discusses recent advances with individualized medicine in CRC, as well as the unmet needs that still exist in this area.

Jonathon B. Cohen, MD, MS, discussed his treatment considerations and decisions for treating patients with mantle cell lymphoma. Cohen made these decisions based on a case scenario of a patient with advanced-stage MCL.

Neoadjuvant chemotherapy with a dose-dense, or accelerated, course of methotrexate, vinblastine, doxorubicin, and cisplatin was more likely to produce a complete pathologic response and extend overall survival than any other chemotherapy regimen in patients with bladder cancer treated with cystectomy, according to a study published in <em>JAMA Oncology</em>.

This week the FDA granted a fast track designation to the novel targeted therapy vofatamab for the treatment of patients with advanced or metastatic urothelial carcinoma who harbor an <em>FGFR3 </em>alteration, according to Rainier Therapeutics, the company developing vofatamab.

Joaquim Bellmunt, MD, PhD, discusses recent immunotherapy advancements in bladder cancer and what future research will look like.